Noteworthy Wednesday Option Activity: FHN, UTHR, SLAB

United Therapeutics (UTHR) saw unusually high options activity with 5,828 contracts traded (≈582,800 underlying shares), equal to ~177.7% of its one‑month average daily volume (327,980 shares); the April 17, 2026 $530 call accounted for 1,910 contracts (~191,000 shares). Silicon Laboratories (SLAB) recorded 6,041 option contracts (≈604,100 underlying shares), ~173.8% of its one‑month average daily volume (347,620 shares), led by 2,460 contracts in the Feb 20, 2026 $200 put (~246,000 shares). The volumes suggest concentrated speculative or hedging flows that could influence intraday liquidity and price moves in both names.

Analysis

Market structure: The concentrated activity (UTHR Apr‑17‑2026 $530 calls = 1,910 contracts ≈191k shares; SLAB Feb‑20‑2026 $200 puts = 2,460 contracts ≈246k shares) implies institutional directional or hedging flow that will force dealer delta/vega hedging into the cash market. Winners: option buyers and any liquidity providers who can monetize elevated IV; losers: passive long holders in SLAB if puts represent fresh downside conviction, and short-dated volatility sellers. The immediate supply/demand imbalance in listed options will lift implied vol and can mechanically move underlying via gamma-hedging over the next days/weeks.

Risk assessment: Tail risks include an adverse FDA decision or trial update for UTHR (binary shock) and a semiconductor capex slowdown or large inventory write‑down for SLAB; both could move >20–40% on event days. Time horizons: expect gamma-driven moves in days–weeks around trade prints, IV re-pricing over months (to expiries Feb/Apr 2026), and fundamental reversion over quarters. Hidden dependencies: trades may be parts of multi-legged structures (collars, index hedges) or blocks tied to corporate activity; monitor block trade prints and 13F changes. Catalysts: upcoming earnings, FDA calendar for UTHR, and semi capex indicators (TSMC guidance, PMI) in the next 30–90 days.

Trade implications: Direct: Establish a defined‑risk directional exposure rather than naked options. For UTHR consider a small (1–2% portfolio) long via Apr‑17‑2026 520/560 call spread to capture upside while limiting premium; for SLAB buy a Feb‑20‑2026 200/160 put spread (1–2%) or a collar if you hold stock. Pair: long UTHR call spread vs short SLAB equity (or short SLAB Jan‑Feb 2026 call overwrites) to play flow divergence. Entry: initiate within 5 trading days; trim at +30% or if IV rises >20% from entry.

Key Decisions for Investors

• Establish a 1–2% position in UTHR via a defined‑risk Apr‑17‑2026 520/560 call spread (buy 520, sell 560) within 5 trading days to capture potential upside signaled by heavy $530 call flow; cap downside premium and target a +30% profit or unwind if IV rises >20%.
• Reduce net cyclicals exposure by 1–3% and initiate a protective SLAB trade: buy Feb‑20‑2026 200/160 put spread sized to cover 1–2% portfolio risk (or equivalent collar) to hedge against semiconductor capex downside ahead of next two quarters of guidance releases.
• Implement a relative‑value pair: long UTHR call‑spread (as above) and short 0.5–1.0% SLAB equity (or short-term calls) to monetize divergent option flows; rebalance if spread P/L moves ±25% or if either stock moves >15% in 10 trading days.
• Monitor three actionable triggers over the next 30–90 days: (1) UTHR FDA/trial calendar and earnings dates, (2) SLAB/semicap guidance and PMIs, (3) option IV moves — unwind directional option exposure if IV increases >25% or if underlying gaps beyond ±15% intraday.